Fundraising Fox

Solaxa

Bethesda, US · Founded 2021 · Delaware corporation · 2 known investors

solaxa.com

Solaxa is a biotech company developing pharmacological and cell-based treatments for peripheral nerve injury and spinal cord injury, drawing on regenerative medicine and nerve technologies. It focuses on drug and drug-device combination products in the field of neurology.

BiotechHealthtechMedical Devicesin /solaxa

Founders & leadership

Solaxa was founded in 2021 by Mark Noble.

MN
Mark NobleChief Science Officer & Co-Founder
CW
Christian WalkerPresident, Chief Development Officer & Founder
BP
Bill PasserChief Financial Officer
BNBrad Navia
Brad NaviaChief Medical Officer

Board

LG
Luis GutierrezBoard director
LS
Lauren SabellaBoard director

Investors · 2

Competitors · 2

by search overlap

Companies competing with Solaxa for the same Google search keywords, organic and paid, via search-intersection analysis.

Reported raises · per SEC filings

Form D private placements

$1.9M disclosed across 4 rounds · 2021–2024

$305KraisedSep 2024 · 4 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Luis GutierrezDirector
  • Lauren SabellaDirector
  • Christian WalkerExecutive Officer, Director
Offering amount
$6M
Amount sold
$305K
First sale
Aug 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$500KraisedMay 2024 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Lauren SabellaDirector
  • Christian WalkerExecutive Officer, Director
  • Luis GutierrrezExecutive Officer, Director
Offering amount
$500K
Amount sold
$500K
First sale
Nov 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$729KraisedMay 2024 · 13 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Christian WalkerExecutive Officer, Director
  • Lauren SabellaDirector
  • Luis GutierrezExecutive Officer, Director
Offering amount
$729K
Amount sold
$729K
First sale
Feb 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$365KraisedMay 2024 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Luis GutierrezExecutive Officer, Director
  • Christian WalkerExecutive Officer, Director
  • Lauren SabellaDirector
Offering amount
$2.1M
Amount sold
$365K
First sale
Apr 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Frequently asked questions

What does Solaxa do?
Solaxa is a biotech company developing pharmacological and cell-based treatments for peripheral nerve injury and spinal cord injury, drawing on regenerative medicine and nerve technologies. It focuses on drug and drug-device combination products in the field of neurology.
Who founded Solaxa?
Solaxa was founded by Mark Noble in 2021.
Who are Solaxa's investors?
Solaxa's investors include Maryland TEDCO, TEDCO.
How much funding has Solaxa raised?
Solaxa has disclosed $1.9M raised across 4 rounds.
Where is Solaxa headquartered?
Solaxa is headquartered in Bethesda, US.